In the UK 53 women are diagnosed with a gynaecological cancer each day, and 21 will die. These cancers make up some of the most common and most fatal diseases that women face, but despite this, gynaecological cancer is neither high profile, nor well funded.
One of our main aims is to fund locally based research into gynaecological cancers including ovarian, uterine, cervical and vulvar cancer, principally at the University of Surrey in Guildford, and within the Gynaeoncology Department.
We also collaborate with research at many of the leading teaching and academic institutions around the UK and internationally.
This progressive approach supported by GRACE funding has led to many novel and cutting edge treatment developments for women facing gynaeacological cancer treatment in Surrey, Hampshire and Sussex.
• Role of HOX genes overexpression in ovarian cancer – PhD
• HXR09 as the therapeutic drug in ovarian cancer – PhD
• Prognostic biomarkers in ovarian cancer – MD
• Further research into p57kip as a biomarker
• Role of circulating tumour cells in ovarian cancer – MD
• Role of HER-2, HER-3, HER-4 and EGRF receptors in ovarian cancer – PhD
• Development of robotic surgery for women with uterine cancers
• Investigating the molecular characteristics of endometrial cancer in young women
• Retrospective study of role of MELF as a prognostic outcome marker
• Psycho-social effects of diagnosis and treatment for cervical cancer
• Role of robotic surgery in cervical cancer
• Fertility-sparing surgery for cervical cancer
• Study into cervical cancer changes during radiotherapy
• Prospective RCT in use of Argon plasma in groin node dissection for vulvar cancer
• Evaluation of avB6 integrin expression in vulvar cancer
• Analysis of gene expression in ovarian borderline Tumours (SLMP) progressing to invasive carcinoma
• Prospective RCT in use of Argon plasma in surgery in advanced ovarian cancer – PhD